24.03.2021 – As a specialist in treating autoimmune disease by restoring normal immune tolerance, Anokion has developed a pipeline of drug candidates targeting different diseases. The company has initiated the first in-human-study for its second candidate ANK-700 for the treatment of Multiple Sclerosis.
Anokion is a Swiss biotech company based at EPFL Innovation Park, focusing on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokin’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.
After bringing its first drug candidate (KAN-101) targeting Celiac diseases into clinical trials, Anokion announced the dosing of the first patient in its first human study to evaluate its second candidate ANK-700 to treat people with relapsing-remitting multiple sclerosis (RRMS). Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system, in which the immune system attacks the myelin sheath in the brain and spinal cord. Anokion‘s ANK-700 aims to re-educate the immune system by inducing antigen-specific tolerance to myelin-based autoantigens to reduce neuroinflammation in the brain and spinal cord.
The MoveS-it Study (Multiple Sclerosis Study of ANK-700 to Assess Safety and Immune Tolerance) is a randomized, double-blind, placebo-controlled, first-in-human study designed to evaluate the safety and tolerability of single and multiple ascending doses of ANK-700. The MoveS-it Study will enrol up to 40 patients at up to 10 sites across the United States.
The trial’s primary endpoint is safety and tolerability, the secondary endpoint is pharmacokinetics (PK) of ANK-700, and other exploratory endpoints include assessments of immunological biomarker responses.
“Multiple sclerosis is a devastating disease that interferes with the brain’s ability to tell the body how to operate, with no curative options. Today’s treatments are primarily anti-inflammatory therapies and symptom management, which are ultimately ineffective in treating patients over the long-term,” said Deborah Geraghty, president and chief executive officer of Anokion. “We are thrilled to start this study with ANK-700, our second product candidate to enter clinical development in the last year. Backed by promising preclinical data in mouse models of MS, we believe ANK-700 has the potential to slow down and even stop disease progression in individuals with MS.”
Source: Press release